Pirenzepine

Pirenzepine (Gastrozepin), an M1 selective antagonist, is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), resulting in an increase in gastric motility and digestion; whereas pirenzepine would inhibit these actions and cause decreased gastric motility leading to delayed gastric emptying and constipation.[1] It has no effects on the brain and spinal cord as it cannot diffuse through the blood–brain barrier.

"Tabe" redirects here. For the assessment tests called TABE, see Tests of Adult Basic Education.

Pirenzepine
Clinical data
Trade namesGastrozepin
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
  • 11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.044.739
Chemical and physical data
FormulaC19H21N5O2
Molar mass351.410 g·mol−1
3D model (JSmol)
  • O=C3c1ccccc1N(C(=O)CN2CCN(C)CC2)c4ncccc4N3
  • InChI=1S/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26) Y
  • Key:RMHMFHUVIITRHF-UHFFFAOYSA-N Y
  (verify)

Pirenzepine has been investigated for use in myopia control.[2][3]

It promotes the homodimerization or oligomerisation of M1 receptors.[4]

See also

References
  1. Stolerman IP (2 August 2010). Encyclopedia of Psychopharmacology. Springer. p. 811. ISBN 978-3-540-68698-9. Retrieved 26 June 2013.
  2. Czepita D (2005). "[Fundamentals of modern treatment of myopia]". Annales Academiae Medicae Stetinensis. 51 (2): 5–9. PMID 16519089.
  3. Walline, Jeffrey J.; Lindsley, Kristina B.; Vedula, S. Swaroop; Cotter, Susan A.; Mutti, Donald O.; Ng, Sueko M.; Twelker, J. Daniel (13 January 2020). "Interventions to slow progression of myopia in children". The Cochrane Database of Systematic Reviews. 1 (9): CD004916. doi:10.1002/14651858.CD004916.pub4. ISSN 1469-493X. PMC 6984636. PMID 31930781.
  4. Pediani JD, Ward RJ, Godin AG, Marsango S, Milligan G (June 2016). "Dynamic Regulation of Quaternary Organization of the M1 Muscarinic Receptor by Subtype-selective Antagonist Drugs". The Journal of Biological Chemistry. 291 (25): 13132–46. doi:10.1074/jbc.M115.712562. PMC 4933229. PMID 27080256.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.